Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis

Wang, Faping; Tang, Xuemei; Wei, Chuanqi; Xu, Linrui; Mao, Hui; Luo, Fengming

doi:10.1016/j.jdermsci.2018.01.016

Cited by 74 publications

(59 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Neurotrophins, especially NGF and its receptor, increase in nerve fibers of PN. 41 Interestingly, however, a recent find showed that none of the tested molecular markers including the neuron-distracting SEMA3A and neuron-attracting NGF altered in lesional and non-lesional skin in PN subjects. 40 Anti-NGF therapy can be used for the treatment of itch in NC/Nga AD mice, which could reduce the increased density of nerve fibers and the instances of scratching.…”

Section: Interleukin-4 and -13mentioning

confidence: 93%

“…In S ezary syndrome patients, NGF expression increases in keratinocytes, and nerve fiber density increases in the area of skin lesions. 41 Interestingly, however, a recent find showed that none of the tested molecular markers including the neuron-distracting SEMA3A and neuron-attracting NGF altered in lesional and non-lesional skin in PN subjects. 30 In addition, the NGF/TrkA/ TRPV1 pathway is considered as an important mechanism of psoriasis.…”

Section: Nerve Growth Factormentioning

confidence: 93%

See 1 more Smart Citation

Inflammatory mediators causing cutaneous chronic itch in some diseases via transient receptor potential channel subfamily V member 1 and subfamily A member 1

Xie

2018

The Journal of Dermatology

View full text Add to dashboard Cite

Chronic itch with an itch–scratch vicious circle is a significant problem in a large amount of diseases. Some of these diseases, such as psoriasis, atopic dermatitis, prurigo nodularis, Sézary syndrome, uremic pruritus, diabetes and jaundice, are common. For a very long time, chronic itch has been a thorny problem with few effective treatments. Because of this, itch researchers and dermatologists seek to find the mechanisms among chronic itch, inflammatory cytokines and neurons. As an immediate area of research focus, we are going to find the peripheral cross‐talk between neurons and skin cells. Two receptors, named transient receptor potential channel vanilloid 1 and transient receptor potential channel ankyrin transmembrane protein 1, have been shown to play important roles in chronic itch. Many advances have been made so far this decade. This review talks about the updated mechanism of itch‐related inflammatory cytokines via transient receptor potential channels in cutaneous chronic itch and corresponding diseases. The search for itch‐related inflammatory mediators and the structure of transient receptor potential channels this decade could deepen our understanding of the mechanism of itch and help us find more treatments of chronic itch in the future.

show abstract

Section: Interleukin-4 and -13mentioning

confidence: 93%

Section: Nerve Growth Factormentioning

confidence: 93%

Inflammatory mediators causing cutaneous chronic itch in some diseases via transient receptor potential channel subfamily V member 1 and subfamily A member 1

Xie

2018

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…[2][3][4] To date, knowledge about the use of biological antipsoriatic therapies in the management of difficult-to-treat body regions is fragmentary, lacking in agreement on the best therapeutic modalities and/or universally shared algorithm. [2][3][4][5][6][7][8][9][10] Here, we report the results of our perspective real-life study, aimed to evaluate the effect of biological drugs on difficult-to-treat psoriatic areas. Subjects were enrolled consecutively from patients attending the Psoriasis Care Center of the Outpatient Clinic of the Section of Dermatology, University of Naples Federico II, between March 2017 and January 2018.…”

Section: Real-life Effectiveness Of Biological Drugs On Psoriatic Difmentioning

confidence: 99%

“…No severe adverse effects have been reported. 8 The main limitation of our series is the lowest number of patients enrolled, but gives valuable preliminary information about the short-term efficacy and safety of dupilumab in realworld patients. Another limitation is having assessed SCORAD instead (or in addition to) EASI score, which may had allowed us to establish further and deeper comparisons to RCT.…”

mentioning

confidence: 99%

Dupilumab: short‐term effectiveness and security in real clinical practice – A retrospective multicentric study

Ruiz‐Villaverde

Domínguez-Cruz

Hita

et al. 2018

Acad Dermatol Venereol

View full text Add to dashboard Cite

“…The ability to measure ‘consumption’ of topical treatment would also provide a useful outcome measure to assess the impact of emerging new drug‐based AD treatments, e.g. interleukin (IL)‐4/IL‐13, IL‐13 or Janus kinase 1 …”

mentioning

confidence: 99%

Quantitative analysis of topical treatments in atopic dermatitis: unexpectedly low use of emollients and strong correlation of topical corticosteroid use both with depression and concurrent asthma

et al. 2019

View full text Add to dashboard Cite

Summary Background Despite decades of use, the actual amounts of topical corticosteroids (TCS) and emollients used in moderate‐to‐severe atopic dermatitis (AD) under real‐world conditions are unknown. Thus, it remains unclear whether inadequate use is widespread. Objectives To quantify the use of TCS and emollients in moderate‐to‐severe AD. Methods Double‐blinded drug prescribing was recorded prospectively at the point of drug dispensing within a catchment area of approximately 450 000 people over a 31‐year period in a population‐based cohort marked by failure of disease control in primary care (n = 844). For each patient, prescribing was recorded over a 12‐month period in order to minimize fluctuations. Results This approach resulted in a near‐complete dataset, which was essentially free of reporting bias and recording bias. Atopic comorbidities matched expected frequencies. Median use of TCS was statistically significantly higher in juvenile patients (age < 16 years) compared with adult patients (49·2 vs. 38·1 g per month), in male vs. female patients (46·8 vs. 29·7 g per month) and in patients receiving concurrent asthma treatment (40·4 vs. 26·7 g per month). TCS use was strongly associated with antidepressant treatment. Emollient use was unexpectedly low with a median of 9·6 g per day (range 1·4–30·1). Results were replicated in an independent validation cohort. Conclusions Deficient use of emollients may be a factor contributing to AD severity. Our analysis showed that the use of TCS does not exceed current guidelines. Accurate quantification of topical treatments provides a widely accessible strategy to measure the real‐world impact of novel AD treatments. What's already known about this topic? Both emollient and topical corticosteroid (TCS) use have been a mainstay of atopic dermatitis (AD) treatment for over 60 years. The actual quantities used by patients under real‐world conditions are unknown. What does this study add? The real‐world use of emollients is fourfold lower than the amount recommended in current guidelines. Underuse of emollients may be a significant factor in disease exacerbation. The use of TCS is significantly higher in male patients and is higher in patients with AD who also have asthma. The use of TCS is strongly associated with concurrent antidepressant treatment.

show abstract

Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis

Abstract: Our analysis provided evidence that dupilumab had an acceptable safety profile and resulted in clinically relevant improvements in signs and symptoms of AD. Dose regimens of 300 mg qw and q2 w seemed to have similar benefits. Further long-term trials are required for confirmation.

Cited by 74 publications

References 25 publications

Inflammatory mediators causing cutaneous chronic itch in some diseases via transient receptor potential channel subfamily V member 1 and subfamily A member 1

Inflammatory mediators causing cutaneous chronic itch in some diseases via transient receptor potential channel subfamily V member 1 and subfamily A member 1

Dupilumab: short‐term effectiveness and security in real clinical practice – A retrospective multicentric study

Quantitative analysis of topical treatments in atopic dermatitis: unexpectedly low use of emollients and strong correlation of topical corticosteroid use both with depression and concurrent asthma

Contact Info

Product

Resources

About

Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis

Abstract: Our analysis provided evidence that dupilumab had an acceptable safety profile and resulted in clinically relevant improvements in signs and symptoms of AD. Dose regimens of 300 mg qw and q2 w seemed to have similar benefits. Further long-term trials are required for confirmation.

Cited by 74 publications

References 25 publications

Inflammatory mediators causing cutaneous chronic itch in some diseases via transient receptor potential channel subfamily V member 1 and subfamily A member 1

Inflammatory mediators causing cutaneous chronic itch in some diseases via transient receptor potential channel subfamily V member 1 and subfamily A member 1

Dupilumab: short‐term effectiveness and security in real clinical practice – A retrospective multicentric study

Quantitative analysis of topical treatments in atopic dermatitis: unexpectedly low use of emollients and strong correlation of topical corticosteroid use both with depression and concurrent asthma

Contact Info

Product

Resources

About

Abstract: Our analysis provided evidence that dupilumab had an acceptable safety profile and resulted in clinically relevant improvements in signs and symptoms of AD. Dose regimens of 300 mg qw and q2 w seemed to have similar benefits. Further long-term trials are required for confirmation.